

INTEGRA LIFESCIENCES HOLDINGS CORP

Form 8-K

June 09, 2011

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 9, 2011**

**Integra LifeSciences Holdings Corporation**

(Exact name of registrant as specified in its charter)

Delaware 000-26244 510317849

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

311 Enterprise Drive, Plainsboro, New Jersey 08536

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 609-275-0500

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statement and Exhibits

SIGNATURES

Exhibit Index

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

*Notes Offering*

On June 9, 2011, Integra LifeSciences Holdings Corporation issued a press release pursuant to Rule 135c under the Securities Act of 1933, as amended, regarding its proposed issuance of up to \$230.0 million in aggregate principal amount of convertible senior notes due 2016 ( the Notes Offering ) through a private placement to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933.

In accordance with Rule 135c(d) under the Securities Act, a copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statement and Exhibits.**

- 99.1 Press Release of Integra LifeSciences Holdings Corporation, dated June 9, 2011 regarding the Notes Offering.
-

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Integra LifeSciences Holdings Corporation

*June 9, 2011*

By: *Stuart M. Essig*

Name: *Stuart M. Essig*

Title: *Chief Executive Officer*

---

**Table of Contents**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued June 9, 2011